Dr Paul Minnis, Specialist in Interstitial Lung Disease and Director of Research & Development in the Northern Trust gives an overview of Respiratory Research and Clinical Trials He talks about the current state of Respiratory Research, the context (Career path), discusses from the Director and Regional Viewpoint and gives an overview of current clinical trials.
FDA approves drug to treat idiopathic pulmonary fibrosis (US FDA)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-idiopathic-pulmonary-fibrosis Please note that this is only approved in the USA – it will have to go through further approval processes before it may be available in the UK & NI. This could take several years.
New results from the FIBRONEER clinical trials for treating pulmonary fibrosis
Summary Two clinical trials have shown promising results on the effects of a new drug called nerandomilast for treating idiopathic pulmonary fibrosis (IPF) – the FIBRONEER-IPF trial, and other forms of progressive pulmonary fibrosis (PPF) – the FIBRONEER-ILD trial. The details have been published in the New England Journal of Medicine (see articles here: FIBRONEER-IPF and FIBRONEER-ILD). The FIBRONEER-IPF trial …